biote (NASDAQ:BTMD) Issues Quarterly Earnings Results

biote (NASDAQ:BTMD) announced its earnings results on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.26), FiscalAI reports. The business had revenue of $44.23 million for the quarter, compared to analyst estimates of $46.12 million. biote had a negative return on equity of 22.69% and a net margin of 3.19%.

Here are the key takeaways from biote’s conference call:

• Negative Sentiment: Second-quarter revenue fell 9.5% to $44.2 million, while procedure revenue declined 13.9% to $30.3 million, pressured by the voluntary pellet recall, supply constraints, clinic attrition, and slower new-clinic productivity.
• Negative Sentiment: Biote lowered its 2026 outlook to revenue above $175 million and adjusted EBITDA above $25 million, compared with prior guidance of more than $190 million and $38 million, respectively; year-over-year procedure revenue is now expected to remain negative in the second half.
• Positive Sentiment: Management said Asteria Health’s supply continuity and inventory levels have normalized, with a second production shift added; reduced reliance on higher-cost third-party pellets is expected to improve gross margins beginning in the third quarter.
• Neutral Sentiment: The company is entering a second strategic phase focused on clinic retention, practitioner engagement, sales-force productivity, and faster new-clinic ramp-up, while also evaluating disciplined inorganic opportunities that could expand its market footprint.
• Positive Sentiment: Dietary-supplement revenue increased 5.7% to $11.4 million, supported by e-commerce and strong adoption among existing clinicians, and is expected to grow at a mid- to high-single-digit rate for 2026; recently resolved legal matters should also reduce future expenses.

biote Price Performance

BTMD stock traded up $0.05 during midday trading on Friday, hitting $1.68. The stock had a trading volume of 116,344 shares, compared to its average volume of 249,452. The company’s 50-day moving average price is $2.21 and its 200 day moving average price is $2.04. The firm has a market cap of $63.28 million, a PE ratio of 15.46 and a beta of 1.64. biote has a 12-month low of $1.27 and a 12-month high of $3.62.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Truist Financial upgraded biote to a “strong-buy” rating in a research report on Monday, June 15th. TD Cowen reissued a “buy” rating on shares of biote in a research report on Friday. Finally, Weiss Ratings upgraded biote from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $2.75.

Institutional Investors Weigh In On biote

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rothschild Wealth LLC acquired a new position in shares of biote in the 4th quarter valued at $380,000. WINTON GROUP Ltd acquired a new stake in shares of biote during the 3rd quarter worth $309,000. State Street Corp raised its position in shares of biote by 17.3% in the 4th quarter. State Street Corp now owns 600,114 shares of the company’s stock worth $1,560,000 after buying an additional 88,402 shares during the period. Bridgeway Capital Management LLC raised its position in shares of biote by 142.1% in the 2nd quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock worth $487,000 after buying an additional 71,053 shares during the period. Finally, Man Group plc boosted its holdings in biote by 419.1% in the second quarter. Man Group plc now owns 64,027 shares of the company’s stock valued at $257,000 after acquiring an additional 51,693 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.